In this study we seek to test the hypothesis that safety and clinical outcomes after cardiac transplantation utilizing HCV NAT+ donor organs as currently performed are acceptable.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Number of donor HCV nucleic-acid testing positive (HCV NAT+) cardiac transplantation
Timeframe: 6.5 years
Failure versus Cure Rate for HCV NAT+ Heart Transplants
Timeframe: 6.5 years
Rate of Primary graft dysfunction (PGD)
Timeframe: 30 days
1 year mortality
Timeframe: 1 Year
Cellular graft rejection rate
Timeframe: 6.5 years
Antibody Mediated Rejection rate
Timeframe: 6.5 years